|
March 26, 2008
|
Affinergy Appoints Two Vice Presidents to Leadership Team
RESEARCH TRIANGLE PARK, N.C., March 26, 2008 - Affinergy, Inc., a Duke University spinout with a proprietary site-specific biological delivery system, announced that it has appointed two Vice Presidents to its leadership team as part of its continued growth towards a product development company. Dr. Carmella S. Moody has joined Affinergy as VP of Regulatory & Quality Assurance and Dr. Bud Nelson has been promoted to VP of Intellectual Property.
"Carmella and Bud are proven executives who bring invaluable domain expertise to Affinergy in their respective fields," said Peyton Anderson, Affinergy's CEO. "They each will play critical leadership roles as we accelerate our programs into the regulatory process while expanding our intellectual property portfolio. Carmella and Bud are highly creative and intelligent professionals who share Affinergy's passion for building a successful business while helping large numbers of patients. We are honored they have accepted these leadership positions and look forward to harnessing their tremendous talents."
Dr. Moody has more than 20 years experience in the life science industry, primarily in the regulatory and clinical areas. She has previously had positions of increasing responsibilities in regulatory affairs, quality, and clinical trials with Constella Group, NextGen Pharma, Glaxo Wellcome, Covance Biotechnology Services, and Cato Research. Dr. Moody has additional experience in product development across a wide range of therapeutic indications. She earned her B.S. from the College of Charleston and earned her M.S. and Ph.D. in Microbiology from NC State University.
Dr. Nelson has over 13 years experience as an intellectual property attorney in the biotech and pharmaceutical industries, and 7 years experience as corporate legal counsel. Prior to joining Affinergy, he was Vice President, R&D and IP, at BioCrystal Ltd., and Chief IP Counsel at Trimeris, Inc (NASDAQ: TRMS). In addition to building and protecting IP, Dr. Nelson innovates in research and development, and is co-inventor on 10 issued U.S. patents. He earned a Ph.D. in Immunology and Microbiology as well as his law degree at the University of Buffalo.
About Affinergy, Inc.
Affinergy develops site-specific biological systems using biofriendly linkers that selectively adhere to proteins, drugs, cells, and biomaterial surfaces in order to kickstart biology toward an intended outcome. Affinergy is focused on developing coatings and medical devices for the orthopedic and cardiovascular markets. Affinergy's technology was patented at Duke University and was awarded 2005 Innovation of the Year by Frost & Sullivan in the category of Medical Device Coatings. For more information, visit www.affinergy.com.
For more information:
Peyton Anderson
Chief Executive Officer
Affinergy, Inc.
919-433-2229
panderson@affinergy.com
|
